Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:GUD TSE:HEXO TSE:HLS NASDAQ:OGI NYSEAMERICAN:ZOM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGUDKnight TherapeuticsC$8.35+11.2%C$6.99C$5.50▼C$8.50C$818.77M-0.21445194,248 shs343,437 shsHEXOHEXOC$0.00C$0.85▼C$4.97C$38.72M2.13253,024 shs72,643 shsHLSHLS TherapeuticsC$4.69-0.2%C$4.47C$4.22▼C$5.77C$146.68M0.3929038,784 shs2,601 shsOGIOrganigram Global$1.39-0.4%$1.41$1.10▼$2.24$194.97M1.5730,725 shs554,179 shsZOMZomedica$0.00$0.09▼$0.16$95.35M1.034.72 million shs790,936 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGUDKnight Therapeutics-0.53%+0.81%-2.34%+28.60%+23.32%HEXOHEXO0.00%0.00%0.00%0.00%0.00%HLSHLS Therapeutics-0.21%+0.21%+7.06%+4.44%+8.05%OGIOrganigram Global0.00%+1.46%+0.72%-6.08%+26.36%ZOMZomedica0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGUDKnight TherapeuticsC$8.35+11.2%C$6.99C$5.50▼C$8.50C$818.77M-0.21445194,248 shs343,437 shsHEXOHEXOC$0.00C$0.85▼C$4.97C$38.72M2.13253,024 shs72,643 shsHLSHLS TherapeuticsC$4.69-0.2%C$4.47C$4.22▼C$5.77C$146.68M0.3929038,784 shs2,601 shsOGIOrganigram Global$1.39-0.4%$1.41$1.10▼$2.24$194.97M1.5730,725 shs554,179 shsZOMZomedica$0.00$0.09▼$0.16$95.35M1.034.72 million shs790,936 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGUDKnight Therapeutics-0.53%+0.81%-2.34%+28.60%+23.32%HEXOHEXO0.00%0.00%0.00%0.00%0.00%HLSHLS Therapeutics-0.21%+0.21%+7.06%+4.44%+8.05%OGIOrganigram Global0.00%+1.46%+0.72%-6.08%+26.36%ZOMZomedica0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGUDKnight Therapeutics 3.00BuyC$6.50-22.16% DownsideHEXOHEXO 0.00N/AN/AN/AHLSHLS Therapeutics 0.00N/AC$6.0028.48% UpsideOGIOrganigram Global 2.33HoldN/AN/AZOMZomedica 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GUD, HLS, HEXO, ZOM, and OGI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/11/2026OGIOrganigram Global ATB Cormark Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Moderate Buy(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGUDKnight TherapeuticsC$450.09M1.82C$2.17 per share3.85C$7.74 per share1.08HEXOHEXOC$124.10M0.00N/A1.55C$3.24 per share0.00HLSHLS TherapeuticsC$55.50M2.63C$0.31 per share15.22C$1.97 per share2.37OGIOrganigram Global$185.07M1.05N/AN/A$1.86 per share0.74ZOMZomedica$25.19M0.00N/AN/A$0.24 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGUDKnight Therapeutics-C$30.73M-C$0.05N/AN/A-1.19%-0.70%0.51%N/AHEXOHEXO-C$273.18M-C$3.41N/AN/A-220.13%-106.39%-14.96%N/AHLSHLS Therapeutics-C$15.53M-C$0.39N/AN/AN/A-22.34%-19.40%-2.89%N/AOGIOrganigram Global-$17.70M$0.149.8934.63N/A6.03%-15.41%-10.49%5/11/2026 (Estimated)ZOMZomedica-$34.53M-$0.06N/AN/AN/A-232.88%-12.47%-11.84%N/ALatest GUD, HLS, HEXO, ZOM, and OGI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q2 2026OGIOrganigram Global-$0.01N/AN/AN/A$50.78 millionN/A5/7/2026Q1 2026GUDKnight TherapeuticsN/AC$0.13N/AC$0.13N/AC$147.59 million3/19/2026Q4 2025GUDKnight TherapeuticsN/AC$0.09N/AC$0.09N/AC$133.20 million3/12/2026Q4 2025HLSHLS TherapeuticsN/A-C$0.05N/A-C$0.05N/AC$20.06 million2/10/2026Q1 2026OGIOrganigram Global-$0.01-$0.02-$0.01$0.11$73.38 million$46.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGUDKnight TherapeuticsN/AN/AN/AN/AN/AHEXOHEXON/AN/AN/AN/AN/AHLSHLS TherapeuticsN/A4.30%N/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/AZOMZomedicaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGUDKnight Therapeutics10.152.391.79HEXOHEXO125.990.410.40HLSHLS Therapeutics80.791.111.01OGIOrganigram GlobalN/A2.731.32ZOMZomedicaN/A10.8210.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGUDKnight Therapeutics23.49%HEXOHEXO7.57%HLSHLS Therapeutics5.38%OGIOrganigram Global34.63%ZOMZomedica8.95%Insider OwnershipCompanyInsider OwnershipGUDKnight Therapeutics45.62%HEXOHEXO3.03%HLSHLS Therapeutics0.37%OGIOrganigram Global0.09%ZOMZomedica4.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGUDKnight Therapeutics72598.06 millionN/ANot OptionableHEXOHEXO69044.00 millionN/ANot OptionableHLSHLS Therapeutics9131.27 millionN/ANot OptionableOGIOrganigram Global1,139140.77 million140.64 millionOptionableZOMZomedica50979.95 million938.89 millionNot OptionableGUD, HLS, HEXO, ZOM, and OGI HeadlinesRecent News About These CompaniesZomedica Corp.: Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in LiquidityMay 6 at 6:52 PM | finanznachrichten.deZomedica Corp. (ZOMDF) Discusses Manufacturing Strategy and Quality Operations for Veterinary Diagnostics and Therapeutics TranscriptApril 24, 2026 | seekingalpha.comZomedica Insider Trading Activity | OTC:ZOMDF | BenzingaApril 7, 2026 | benzinga.comZomedica Corp. (ZOMDF) Discusses the Equine Veterinary Market Opportunity TranscriptMarch 28, 2026 | seekingalpha.comZomedica Corp.: Zomedica Announces Strategic Collaboration with Boehringer Ingelheim to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA PlatformMarch 19, 2026 | finanznachrichten.deZomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and ...March 16, 2026 | pharmiweb.comPZomedica Corp.: Zomedica to Review 2025 Financial Results and Highlight Equine Market Opportunity During March 27th "Fourth Friday at Four" Investor WebinarMarch 10, 2026 | finanznachrichten.deZomedica Corp. (ZOMDF) Discusses R&D Strategy and Innovation in Veterinary Diagnostic and Therapeutic Technologies TranscriptFebruary 27, 2026 | seekingalpha.comZomedica Corp.: Zomedica Expands Distribution of TRUVIEW Digital Microscopy Platform Through National Agreement with Moichor, a Leader in Veterinary PathologyFebruary 25, 2026 | finanznachrichten.deZomedica Corp.: Zomedica Announces "Fourth Friday at Four" Webinar on February 27th Focused on Research & Development and Its Innovation PipelineFebruary 5, 2026 | finanznachrichten.deZomedica Corp. (ZOMDF) Discusses Technology and Digital Innovation Driving Growth in Animal Health TranscriptJanuary 23, 2026 | seekingalpha.comZomedica Corp.: Zomedica Expands its TRUVIEW Microscopy Platform with AI Diagnostic Interpretation, Growing its Market OpportunityJanuary 23, 2026 | finanznachrichten.deZomedica Corp.: Zomedica Announces "Fourth Friday at Four" Webinar on January 23rd Focused on Digital Innovation & Technology-Driven GrowthJanuary 14, 2026 | finanznachrichten.deModern therapies for patients with chronic painDecember 16, 2025 | dvm360.comDZomedica Corp. (ZOMDF) Q3 2025 Earnings Call TranscriptNovember 21, 2025 | seekingalpha.comFull-body therapy bed is launched for pain management and mobility supportOctober 24, 2025 | dvm360.comDZomedica Corp.: Zomedica Announces Launch of the Assisi Loop Lounge, Scientifically Backed tPEMF Therapy for PetsOctober 23, 2025 | finanznachrichten.deZomedica Corp.: Zomedica Expands TRUFORMA Diagnostic Platform with Addition of Feline Use to Cobalamin & Folate AssaySeptember 23, 2025 | finanznachrichten.deZomedica Corp.: Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on TRUVIEW Digital Cytology Microscope - Transforming Veterinary ImagingSeptember 12, 2025 | finanznachrichten.deZomedica Corp.: Zomedica and UXR Announce Expanded Distribution Agreement in CanadaSeptember 10, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGUD, HLS, HEXO, ZOM, and OGI Company DescriptionsKnight Therapeutics TSE:GUDC$8.35 +0.84 (+11.19%) As of 03:52 PM EasternKnight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.HEXO TSE:HEXOHEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada.HLS Therapeutics TSE:HLSC$4.69 -0.01 (-0.21%) As of 03:38 PM EasternHLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world.Organigram Global NASDAQ:OGI$1.38 -0.01 (-0.36%) Closing price 03:58 PM EasternExtended Trading$1.38 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.Zomedica NYSEAMERICAN:ZOMZomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally IonQ Just Posted a Breakout Quarter—But 1 Problem Remains Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
